Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced ...

The Phase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate ...

Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints including adaptive behavior, cognition and hearing, and ...

It sounds like Lilly did just that. The U.S. pharma announced on Wednesday that it was paying $14 per share of Ventyx—more ...

The Sycamore Youth Center has announced registration is open for after-school classes for the winter and spring semester. Classes run from Jan. 26 through May 1, with courses offered to students in ...

Navodaya Vidyalaya Samiti has released NVS Class 9 LEST Admit Card 2026. Candidates who will appear for Class 9 Lateral Entry Selection Test can find the admit card link on the official website of NVS ...

Biomed Industries to Advance NA-931 Into Two Global Phase 3 Trials as Monotherapy and in Combination With Semaglutide and Tirzepatide for Obesity Advancing NA-931 into two Phase 3 programs as ...

Enrollment in Flathead County public, private and home schools declined for the third consecutive year while still reflecting ...

Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens Designed to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735 ...

Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced that dosing is complete in ...

Takeda and Protagonist Therapeutics have submitted a new drug application to the FDA for rusfertide for adults with ...

Company also announces renaming of Toliara Project to Vara Mada to better reflect the project's positive benefits to Madagascar and its global ...